Keywords: Takeda, Actos, Diabetes, France, Cancer risk, EMA
France suspends sales of Takeda’s Actos on cancer risk concerns
Article | 10 June 2011
Sales of blockbuster diabetes drug Actos (pioglitazone), from Japan’s leading drugmaker Takeda Pharmaceuticals (TYO: 4502), have been suspended in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
